# Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

> **NCT07389629** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 25 (estimated)

## Conditions studied

- Iparomlimab and Tuvonralimab
- Clear Cell Renal Cell Carcinoma
- Neoadjuvant Therapy

## Interventions

- **DRUG:** QL1706 Combined With Lenvatinib

## Key facts

- **NCT ID:** NCT07389629
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-21
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389629, "Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07389629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*